Two replicate phase 3 trials of GB-0895, an anti-thymic stromal lymphopoietin antibody, are enrolling adults and adolescents ...

Dupilumab, a fully human monoclonal antibody, inhibits the signaling of the interleukin 4 (IL-4) and IL-13 pathways.

This year’s top asthma and respiratory disorder story focused on the pushback from multiple advocacy groups following ...

GSK plc (LSE/NYSE: GSK) said the U.S. Food and Drug Administration has approved Exdensur, a twice-yearly biologic treatment ...

The injectable therapy contain antibodies that dampen inflammation in the lungs and is set to revolutionise the way severe ...

Tezepelumab may allow patients with severe, uncontrolled asthma who are oral corticosteroid-dependent to decrease their OCS use.

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Chiesi USA's asthma inhaler ...

Only 15% of patients were adherent to ICS therapy 3 months after their asthma exacerbation, and less that one-fourth of those remained adherent 9 months later. Improved adherence to inhaled ...

When your child has asthma, an asthma action plan can help you respond quickly to symptoms and prevent emergency department visits and hospitalizations. “An asthma action plan … outlines which ...

NICE, BTS, and SIGN guidelines: In November 2024, the National Institute for Health and Care Excellence (NICE) published the most significant update to UK guidelines in recent years. Jointly released ...

Asthma is a chronic inflammatory condition marked by an imbalance in the immune response within the airways. According to Lancet, asthma affects around 339 million people globally. While conventional ...